Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > June 28, 2022
Daily News
June 28, 2022
- Brexpiprazole Cuts Alzheimer’s Agitation in PIII Study: Otsuka/Lundbeck
June 28, 2022
- Astellas’ Pompe Gene Therapy Trial Hit with FDA Clinical Hold
June 28, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- Novo Japan Seeks Thumbs-Up for Sogroya Use in Short Stature
June 28, 2022
- Mitsubishi Tanabe, EditForce Join Forces for Discovery of Gene Therapy in CNS
June 28, 2022
- Kyowa Kirin Gets EU Backing for Crysvita’s Label Expansion into TIO
June 28, 2022
- Kobayashi Kako to Withdraw Marketing License Next April
June 28, 2022
- Daiichi Sankyo CEO Snags 341 Million Yen in FY2021: Securities Filing
June 28, 2022
- Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…